Contact this trialFirst, we need to learn more about you.
BH3 Mimetic
Venetoclax for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase < 1
Birmingham, Alabama
This trial suggests a new therapy for IPF based on targeting a mitochondrial protein, Bcl-2, to induce apoptosis of macrophages and reduce fibrosis. ABT-199, a Bcl-2 inhibitor, has been shown effective in preclinical and clinical trials in another disease.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.